SCH900776 MK-8776 SCH-900776 MK8776 is a small molecule inhibitor of the checkpoint kinase 1 (Chk1), which is involved in DNA damage response and repair. The drug has promising potential in cancer treatment, as it can enhance the sensitivity of cancer cells to chemotherapy and radiotherapy. In this article, we will discuss the chemical, health benefits, mechanism, safety, and dosing information of SCH900776 MK-8776 SCH-900776 MK8776.
Chemical Properties: Chemical name: 3-[(4S)-4-(3-Fluorophenyl)-2-pyridinyl]-8-nitro- [1,2,4]triazolo[4,3-a]pyridine Molecular formula: C17H10F1N6O2 Formula weight: 362.30 g/mol CAS No: 891494-63-6
Top ten Google Keywords:
Synonyms: MK-8776 891494-63-6
Health Benefits: SCH900776 MK-8776 SCH-900776 MK8776 is a potential drug candidate for cancer treatment. The drug works by inhibiting Chk1, which is a critical enzyme that regulates the cell cycle and DNA damage response. By blocking Chk1, SCH900776 MK-8776 SCH-900776 MK8776 can enhance cancer cell sensitivity to chemotherapy and radiation, potentially leading to better outcomes for cancer patients.
Potential Effects: SCH900776 MK-8776 SCH-900776 MK8776 has demonstrated significant promise in various preclinical studies in enhancing the sensitivity of cancer cells to chemotherapy and radiotherapy. In particular, the drug has shown efficacy in enhancing the efficacy of cisplatin and gemcitabine, two chemotherapy agents used in the treatment of various malignancies, including lung and pancreatic cancer.
Product Mechanism: SCH900776 MK-8776 SCH-900776 MK8776 works by inhibiting Chk1, a critical checkpoint kinase involved in DNA damage response and repair. By inhibiting the function of Chk1, the drug prevents cells from repairing DNA damage and induces cell death, leading to improved sensitivity to chemotherapy and radiotherapy.
Safety: SCH900776 MK-8776 SCH-900776 MK8776 has been shown to be generally safe in clinical trials. However, further studies are necessary to determine the long-term effects and safety of the drug.
Side Effects: The most commonly reported side effects of SCH900776 MK-8776 SCH-900776 MK8776 include nausea, vomiting, and diarrhea. In rare cases, the drug can cause severe toxicity, such as myelosuppression.
Dosing Information: SCH900776 MK-8776 SCH-900776 MK8776 is typically administered orally, and the recommended dose depends on the patient's condition and response to treatment. In clinical trials, the drug has been administered at doses ranging from 100 to 300 mg/day, with treatment duration ranging from days to several weeks.
Conclusion: SCH900776 MK-8776 SCH-900776 MK8776 is a promising checkpoint kinase inhibitor with potential applications in cancer therapy. As a Chk1 inhibitor, it can enhance the sensitivity of tumor cells to chemotherapy and radiotherapy, potentially improving the quality of life and survival of cancer patients. However, the long-term effects and safety of the drug require further investigation. Clinical trials are ongoing to confirm its efficacy and establish appropriate dosing regimens to maximize therapeutic benefits while minimizing potential side effects. Overall, SCH900776 MK-8776 SCH-900776 MK8776 is a promising anti-cancer drug candidate worth further exploration.
